EDITORIAL
SERAPHIN trial: raising the standards in the treatment of pulmonary arterial hypertension patients
 
More details
Hide details
1
Respiratory Intensive Care Unit, Aristotle University of Thessaloniki, G.H. “G. Papanikolaou”, Exohi, Thessaloniki, Greece
 
2
1st Department of Pneumonology, Hospital for Diseases of the Chest “SOTIRIA”, Medical School, National and Kapodistrian University of Athens, Athens, Greece
 
 
Corresponding author
Demosthenes Bouros   

1st Department of Pneumonology, Hospital for Diseases of the Chest “SOTIRIA”, Medical School, National and Kapodistrian University of Athens, Messogion 152, Athens 11527, Greece
 
 
Pneumon 2015;28(1):18-19
 
KEYWORDS
 
REFERENCES (5)
1.
Peacock A, Keogh A, Humbert M. Endpoints in pulmonary arterial hypertension: the role of clinical worsening. Curr Opin Pulm Med 2010; 16(Suppl. 1):S1-9. doi: 10.1097/01.mcp. 0000370205.22885.98.
 
2.
Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60:1192-1201. doi: 10.1016/j.jacc.2012.01.083.
 
3.
Pulido T, Adzerikho I, Channick RN, et al; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369:809-818. doi: 10.1056/NEJMoa1213917.
 
4.
Burger CD, Long PK, Shah MR, et al. Characterization of firsttime hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. Chest 2014; 146:1263-1273. doi: 10.1378/chest.14-0193.
 
5.
Channick RN, Delcroix M, Ghofrani HA, et al. Effect of Macitentan on Hospitalizations: Results From the SERAPHIN Trial. JACC Heart Fail 2015; 3:1-8. doi: 10.1016/j.jchf.2014.07.013.
 
eISSN:1791-4914
ISSN:1105-848X
Journals System - logo
Scroll to top